Research background
Stroke has become the largest disabling and lethal disease in China, with about 2 million stroke patients dying every year. It is estimated that there will be 31 million stroke patients in China by 2030. Most of the existing neuroprotective agents used for the treatment of stroke are single-target drugs, and most of them act on the middle and downstream links of secondary neuronal injury, with limited clinical efficacy. The new drug candidate TK-X01 can simultaneously target the three ion channels of Na+/Cl-/P2X receptor, and its target is located in the upstream of secondary brain injury, which can extensively intervene and affect the middle and downstream signaling pathways, and is conducive to synergistically exert the ideal neuroprotective efficacy. So far, neuroprotective agents that simultaneously target the above ion channels are still lacking in the international community.
01
Project introduction
A company is an innovation-driven enterprise committed to the research and development of ion channel targeting drugs. The research and development pipeline is derived from long-term medical clinical practice, and can simultaneously target voltage, ligand-gated and ATP-dependent ion channels, which has great clinical value and application prospect in the prevention and treatment of stroke, Parkinson's disease, retinal macular degeneration and Alzheimer's disease and other CNS diseases.
TK-X01 is an innovative drug in the class 2.2+2.4 of chemical drugs, which is used to improve neurological symptoms, activities of daily living and dysfunction caused by ischemic stroke.
02
Technical introduction
TK-X01 project is independent research and development of the company, Sichuan University West China College of Pharmacy as the main research unit. The project has completed all pre-clinical research work and declared 3 technical invention patents, including 1 PCT patent, which has entered the substantive examination stage. The research content of the project involves (1) computational pharmacy; (2) Molecular pharmacology (neuroelectrophysiological patch clamp technique); (3) Key technologies such as cell & animal pharmacodynamics.
02
Research stage
In September 2023, the clinical trial approval has been obtained, and the clinical study is planned to start in January 2024.
Financing demand
